The First International Conference on Vascular Targeting: Meeting overview

Philip E. Thorpe, David J. Chaplin, David C. Blakey

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

The First International Conference on Vascular Targeting focused on vascular targeting agents (VTAs) that occlude or destroy the pre-existing blood vessels of solid tumors. The VTAs cause a rapid shutdown in the blood supply to the tumor that kills tumor cells by depriving them of oxygen and nutrients. The VTAs are distinct from antiangiogenic agents, which prevent new blood vessel formation. Two major types of VTAs are being developed for cancer: the ligand-directed VTAs that use antibodies, peptides, and growth factors to deliver toxins, procoagulants, and proapoptotic effectors to tumor endothelium, and the small molecule VTAs that do not specifically localize to tumor endothelium but exploit pathophysiological differences between tumor and normal tissue endothelia to induce acute vascular shutdown in tumors. Both approaches were described at the meeting and highlighted the variety of VTAs in preclinical development, their selectivity for tumor endothelium, their rapid antitumor effects, and the improved activity seen when combined with other anticancer approaches (antiproliferative chemotherapeutic drugs, radiation, radiolabeled antibodies, nitric oxide synthetase inhibitors, and antiangiogenic agents). Early clinical studies were summarized for the small molecule VTAs: the antitubulin drugs, combretastatin A4 phosphate (CA4P) and ZD6126, and the flavonoid, 5,6-dimethylxanthenone-4-acetic acid (DMXAA). The agents lacked the bone marrow and gastrointestinal toxicities associated with antiproliferative chemotherapy. As a marker of biological effect, blood flow reductions in tumors were measured using magnetic resonance imaging or positron emission tomography for all of the agents tested, and single-agent clinical activity was seen. These agents are now being evaluated in combined modality studies to see whether the impressive results obtained in experimental models can be translated into humans.

Original languageEnglish (US)
Pages (from-to)1144-1147
Number of pages4
JournalCancer Research
Volume63
Issue number5
StatePublished - Mar 1 2003

Fingerprint

Blood Vessels
Neoplasms
Endothelium
Angiogenesis Inhibitors
vadimezan
Vascular Tissue Neoplasms
Antibodies
Flavonoids
Nitric Oxide Synthase
Pharmaceutical Preparations
Positron-Emission Tomography
Intercellular Signaling Peptides and Proteins
Theoretical Models
Biomarkers
Bone Marrow
Magnetic Resonance Imaging
Radiation
Oxygen
Ligands
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thorpe, P. E., Chaplin, D. J., & Blakey, D. C. (2003). The First International Conference on Vascular Targeting: Meeting overview. Cancer Research, 63(5), 1144-1147.

The First International Conference on Vascular Targeting : Meeting overview. / Thorpe, Philip E.; Chaplin, David J.; Blakey, David C.

In: Cancer Research, Vol. 63, No. 5, 01.03.2003, p. 1144-1147.

Research output: Contribution to journalArticle

Thorpe, PE, Chaplin, DJ & Blakey, DC 2003, 'The First International Conference on Vascular Targeting: Meeting overview', Cancer Research, vol. 63, no. 5, pp. 1144-1147.
Thorpe PE, Chaplin DJ, Blakey DC. The First International Conference on Vascular Targeting: Meeting overview. Cancer Research. 2003 Mar 1;63(5):1144-1147.
Thorpe, Philip E. ; Chaplin, David J. ; Blakey, David C. / The First International Conference on Vascular Targeting : Meeting overview. In: Cancer Research. 2003 ; Vol. 63, No. 5. pp. 1144-1147.
@article{d853c9a4b0cb491e821dcce56a0aa6bb,
title = "The First International Conference on Vascular Targeting: Meeting overview",
abstract = "The First International Conference on Vascular Targeting focused on vascular targeting agents (VTAs) that occlude or destroy the pre-existing blood vessels of solid tumors. The VTAs cause a rapid shutdown in the blood supply to the tumor that kills tumor cells by depriving them of oxygen and nutrients. The VTAs are distinct from antiangiogenic agents, which prevent new blood vessel formation. Two major types of VTAs are being developed for cancer: the ligand-directed VTAs that use antibodies, peptides, and growth factors to deliver toxins, procoagulants, and proapoptotic effectors to tumor endothelium, and the small molecule VTAs that do not specifically localize to tumor endothelium but exploit pathophysiological differences between tumor and normal tissue endothelia to induce acute vascular shutdown in tumors. Both approaches were described at the meeting and highlighted the variety of VTAs in preclinical development, their selectivity for tumor endothelium, their rapid antitumor effects, and the improved activity seen when combined with other anticancer approaches (antiproliferative chemotherapeutic drugs, radiation, radiolabeled antibodies, nitric oxide synthetase inhibitors, and antiangiogenic agents). Early clinical studies were summarized for the small molecule VTAs: the antitubulin drugs, combretastatin A4 phosphate (CA4P) and ZD6126, and the flavonoid, 5,6-dimethylxanthenone-4-acetic acid (DMXAA). The agents lacked the bone marrow and gastrointestinal toxicities associated with antiproliferative chemotherapy. As a marker of biological effect, blood flow reductions in tumors were measured using magnetic resonance imaging or positron emission tomography for all of the agents tested, and single-agent clinical activity was seen. These agents are now being evaluated in combined modality studies to see whether the impressive results obtained in experimental models can be translated into humans.",
author = "Thorpe, {Philip E.} and Chaplin, {David J.} and Blakey, {David C.}",
year = "2003",
month = "3",
day = "1",
language = "English (US)",
volume = "63",
pages = "1144--1147",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - The First International Conference on Vascular Targeting

T2 - Meeting overview

AU - Thorpe, Philip E.

AU - Chaplin, David J.

AU - Blakey, David C.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - The First International Conference on Vascular Targeting focused on vascular targeting agents (VTAs) that occlude or destroy the pre-existing blood vessels of solid tumors. The VTAs cause a rapid shutdown in the blood supply to the tumor that kills tumor cells by depriving them of oxygen and nutrients. The VTAs are distinct from antiangiogenic agents, which prevent new blood vessel formation. Two major types of VTAs are being developed for cancer: the ligand-directed VTAs that use antibodies, peptides, and growth factors to deliver toxins, procoagulants, and proapoptotic effectors to tumor endothelium, and the small molecule VTAs that do not specifically localize to tumor endothelium but exploit pathophysiological differences between tumor and normal tissue endothelia to induce acute vascular shutdown in tumors. Both approaches were described at the meeting and highlighted the variety of VTAs in preclinical development, their selectivity for tumor endothelium, their rapid antitumor effects, and the improved activity seen when combined with other anticancer approaches (antiproliferative chemotherapeutic drugs, radiation, radiolabeled antibodies, nitric oxide synthetase inhibitors, and antiangiogenic agents). Early clinical studies were summarized for the small molecule VTAs: the antitubulin drugs, combretastatin A4 phosphate (CA4P) and ZD6126, and the flavonoid, 5,6-dimethylxanthenone-4-acetic acid (DMXAA). The agents lacked the bone marrow and gastrointestinal toxicities associated with antiproliferative chemotherapy. As a marker of biological effect, blood flow reductions in tumors were measured using magnetic resonance imaging or positron emission tomography for all of the agents tested, and single-agent clinical activity was seen. These agents are now being evaluated in combined modality studies to see whether the impressive results obtained in experimental models can be translated into humans.

AB - The First International Conference on Vascular Targeting focused on vascular targeting agents (VTAs) that occlude or destroy the pre-existing blood vessels of solid tumors. The VTAs cause a rapid shutdown in the blood supply to the tumor that kills tumor cells by depriving them of oxygen and nutrients. The VTAs are distinct from antiangiogenic agents, which prevent new blood vessel formation. Two major types of VTAs are being developed for cancer: the ligand-directed VTAs that use antibodies, peptides, and growth factors to deliver toxins, procoagulants, and proapoptotic effectors to tumor endothelium, and the small molecule VTAs that do not specifically localize to tumor endothelium but exploit pathophysiological differences between tumor and normal tissue endothelia to induce acute vascular shutdown in tumors. Both approaches were described at the meeting and highlighted the variety of VTAs in preclinical development, their selectivity for tumor endothelium, their rapid antitumor effects, and the improved activity seen when combined with other anticancer approaches (antiproliferative chemotherapeutic drugs, radiation, radiolabeled antibodies, nitric oxide synthetase inhibitors, and antiangiogenic agents). Early clinical studies were summarized for the small molecule VTAs: the antitubulin drugs, combretastatin A4 phosphate (CA4P) and ZD6126, and the flavonoid, 5,6-dimethylxanthenone-4-acetic acid (DMXAA). The agents lacked the bone marrow and gastrointestinal toxicities associated with antiproliferative chemotherapy. As a marker of biological effect, blood flow reductions in tumors were measured using magnetic resonance imaging or positron emission tomography for all of the agents tested, and single-agent clinical activity was seen. These agents are now being evaluated in combined modality studies to see whether the impressive results obtained in experimental models can be translated into humans.

UR - http://www.scopus.com/inward/record.url?scp=0037373826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037373826&partnerID=8YFLogxK

M3 - Article

C2 - 12615734

AN - SCOPUS:0037373826

VL - 63

SP - 1144

EP - 1147

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -